<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ920116-0047</DOCNO><DOCID>920116-0047.</DOCID><HL>   OTC Focus:   Nasdaq Index Climbs 0.81% to High,   But Biotech Stocks Display Weakness   ----   By Dave Pettit   Staff Reporter of The Wall Street Journal</HL><DATE>01/16/92</DATE><SO>WALL STREET JOURNAL (J), PAGE C6</SO><IN>STOCK INDEXES (NDX)OTC GENERAL MARKET COMMENT (OTC)STOCK MARKET, OFFERINGS (STK)U.S. STOCK MARKET STATISTICS (STT)</IN><NS>STOCK AND OTHER INDEXES (NDX)STOCK andamp; OTHER MARKET NEWS (STK)</NS><RE>NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   NEW YORK -- Nasdaq issues jumped to another record, butbiotechnology stocks were hit hard by what some saw as arotation into the computer technology group.   While many computer and semiconductor listings notchedsizable gains, medical technology stocks fell sharply.Microsoft leapt 3 1/4 to a new 52-week high of 131 1/2. Amgenslid 4 1/2 to 73.</LP><TEXT>   &quot;We see a definite rotation out of biotechnology, out ofdrugs, and into technology,&quot; said Glenn Parker, managingdirector of OTC institutional trading at Hambrecht andamp; Quist.He said orders related to technology stocks yesterday wereweighted 3-to-1 to the &quot;buy&quot; side.   The overall market recovered from a late morning sell-offto close sharply higher. The Nasdaq Composite Index rose5.07, or 0.81%, to 630.82, topping the alltime high set a dayearlier. Advancing issues led decliners, 1,373 to 896.   National Market System volume swelled to 243,750,000shares, the third highest one-day level on record, up from220,890,000 Tuesday.   The New York Stock Exchange's gains were more subdued thanNasdaq's, but volume on the exchange was brisk. The Dow JonesIndustrial Average rose 12.30, or 0.38%; Big Board volumetopped 300 million shares.   Joyce Lonergan, a biotechnology analyst for Cowen andamp; Co.,said that after that group's strong recent gains, some peoplewere &quot;getting scared about the valuations.&quot; Market observersnoted several events that triggered profit-taking.   Merrill Lynch analyst Stuart Weisbrod, for example,slashed his fiscal 1992 earnings estimate for Immunex to 65cents a share from a previous forecast of $1.20 a share. Theanalyst said the company's research and development costswill rise because of plans to hasten development of someearly-stage products. Immunex shares lost 4 1/4 to 59.   Meanwhile, Biogen, whose shares tumbled 2 to 38 1/2,reported fourth-quarter net of three cents a share, down fromfour cents a share last year, and below theseven-cent-a-share mean analyst estimate reported by FirstCall, a unit of Thomson Financial Networks.   Richard Rosen, a vice president at D.H. Blair andamp; Co., saidthe biotechnology group's weakness could foreshadow acorrection in the overall Nasdaq market. He expects medicaltechnology issues to fall more sharply than the market ingeneral if a pullback does emerge.   L. Keith Mullins, head of Smith Barney, Harris Upham'semerging growth stock group, said gains amongsemiconductor-related stocks helped lead the technology grouphigher. Brooktree added 1 to 17 3/4, while Intel rose 1 1/2to 56.   After the market closed, Intel reported fourth-quarter netincome of 90 cents a share, up from 80 cents a share a yearago and above the mean First Call estimate of 82 cents ashare. Revenue for the quarter reached $1.2 billion, up from$1 billion.   Trimedyne dropped 3 to 11 5/8 after rallying sharply sinceFriday on receipt of Food and Drug Administration approvalfor a laser product.   Elsewhere, Information Resources jumped 4 3/8 to 35.Morgan Stanley analyst Kurt Feuerman initiated coverage ofthe stock with a &quot;buy&quot; recommendation, Dow Jones ProfessionalInvestor Report said. The Chicago database and softwareconcern was added to Morgan Stanley's Emerging Growth FocusList.   Ecogen gained 1 1/4 to 14 3/8. It entered an agreementwith Pfizer under which the companies will jointly developimproved methods for making biopesticides.   KnowledgeWare rose 4 1/4 to 19 1/4. Although the companydenied a report that it had talks to be acquired by eitherComputer Associates or Dun andamp; Bradstreet, it said it has hadpreliminary discussions with other parties regarding possiblejoint ventures or other business combinations. Separately,the company estimated its earnings for the second quarter,ended last month, at eight cents to 11 cents a share, downfrom 25 cents a share a year ago.   Radius advanced 1 3/4 to 11 3/8. It posted net income of15 cents a share for its first quarter, ended Dec. 31, upfrom year-ago earnings of 13 cents a share. Sales climbed to$36.8 million from $31 million.   ADC Telecommunications lost 4 to 24 3/4 after it projecteda loss for the first quarter, ended Jan. 31, compared withyear-ago net of 50 cents a share. It expects revenue for theperiod to be down 10% to 15% from last year and said it willtake a charge related to staff reductions.   Geriatric andamp; Medical rose 5/8 to 3 7/8. It recordedearnings of 16 cents a share for the second quarter, endedNov. 30, up from net from operations of 13 cents a share ayear earlier.   ---   NASDAQ INTERNATIONAL: Two more U.S. brokerage firms havesigned up to trade OTC stocks in the pre-dawn trading due tostart Monday with the launch of Nasdaq International, thecomputerized trading system that will allow European and U.S.brokerage firms to trade larger U.S. stocks from 3:30 a.m.EST to 9 a.m. Sherwood Group Inc., listed on the AmericanStock Exchange, said yesterday that the New York brokeragefirm will have about seven employees on hand in the earlymorning to make markets in more than 1,400 National MarketSystem stocks, or the largest OTC stocks, eligible fortrading on Nasdaq International. Herzog, Heine andamp; Geduld, alsoof New York, will have a &quot;skeleton crew&quot; working theearlybird shift, Herzog President E. E. &quot;Buzz&quot; Geduld said.Both firms said they expect initial demand will be light.</TEXT></DOC>